Claroid Pharma Files IPO Draft Papers To Offer 1.26 Crore Shares: Here Are The Key Risk Factors
A ipo & listings development with market-wide reach.
· NDTV Profit
The company plans to utilise the net proceeds from the fresh issue towards funding capital expenditure for setting up a new pharmaceutical manufacturing facility on its existing land.
The analysis
Listing activity is a read on risk appetite — a hot primary market usually means a confident secondary one.
Market context
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Reliance shares may be a cheaper way to buy Jio Platforms after its listing
Bharti Airtel's Sunil Bharti Mittal backs Jio's public listing, says ‘looking forward to a very successful IPO’
Vodafone Idea zooms 12% after FPO sees 6x subscription; focus shifts to allotment, listing
PSP Projects share gains 4% on launching Rs 244-crore QIP
Indus Towers gains 4% after CLSA upgrade to #39;buy#39; on Voda Idea FPO